At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Relevant orthopaedic surgery (procedure)
- How long the study runs
- Study runs about 119 months (dates as stated)
- About the drug or intervention
- Relevant orthopaedic surgery — procedure: Inclusion criteria is purposefully broad to examine a range of discarded bone waste.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years to 110 Years
- Who
- All
- Number of participants
- 2,000
- Started
- 2023-01-12
- Last checked
- 2026-08
Plain English Summary
What is this study?
- • Testing a new treatment for osteoporosis
- • Clinical study - 2,000 participants
- • Diseases of bone associated with ageing, including osteoporosis (OP) and osteoarthritis (OA), reduce bone mass, bone strength and joint integrity
Who can take part?
- • Ages 18 Years to 110 Years
- • Diagnosed with osteoporosis
Where?
- • London - Harley Street Specialist Hospital
- • London - Barts Health NHS Trust
- • London - Chase Farm Hospital
- • London - Fitzrovia Hospital/QASMC
- • +4 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Diseases of bone associated with ageing, including osteoporosis (OP) and osteoarthritis (OA), reduce bone mass, bone strength and joint integrity. Current non-surgical approaches are limited to pharmaceutical agents that are not disease modifying and have poor patient tolerability due to side effect profiles. Developing a fundamental understanding of cellular bone homeostasis, including how key cell types affect tissue health, and offering novel therapeutic targets for prevention of bone disease is therefore essential. This is the focus of OSTEOMICS. A number of factors have been linked to increased risk of bone disease, including genetic predisposition, diet, smoking, ageing, autoimmune disorders and endocrine disorders. In our study, we will recruit patients undergoing elective and non-elective orthopaedic surgery and obtain surgical bone waste for analysis. This will capture a cohort of patients with bone disorders like OP and OA, in addition to patients without overt clinical bone disease. We will study the relationship between the molecular biology of bone cells, bone structure, genetics (DNA) and environmental factors with the aim of identifying and validating novel therapeutic targets. We will leverage modern single cell technologies to understand the diversity of cell types found in bone. These technologies have now led to the characterisation of virtually every tissue in the body, however bone and bone-adjacent tissues are massively underrepresented due to the anatomical location and underlying technical challenges. Early protocols to demineralise bone and perform single cell profiling have now been developed. We will systematically scale up these efforts to observe how genetic variation at the population level leads to alterations in bone structure and quality. Over the next 10 years, we will generate data to comprehensively characterise bone across health and disease, use machine learning to drive analysis, and experimentally validate hypotheses - which will ultimately contribute to developing the next generation of therapeutic agents.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 110 Years
- Who can join: All genders
What the study is looking for
- ✓Patients with osteoarthritis undergoing total joint arthroplasty, osteotomy or arthrodesis of any joint (including...
- ✓Patient with fractured neck of femurs undergoing hemiarthroplasty or total hip arthroplasty, or other internal...
- ✓Patients undergoing acute low-velocity or fragility fracture fixation surgery.
- ✓Patients aged between 18-110 years old with capacity to consent.
- ✓We note that our inclusion criteria is purposefully broad as we aim to deduce trends across a wide range of...
Who cannot take part
- ✗Patients unable to provide agreement to take part.
- ✗Patients with suspected/established underlying cancer.
- ✗Patients with suspected/established osteomyelitis.
- ✗Patients with suspected/established bloodborne disease
- ✗Patients who are currently a subject of a clinical trial involving an investigational medicinal product.
See the full criteria
Where Is This Study? (8 UK sites)
Harley Street Specialist Hospital
London W1G 8HU, United Kingdom
Barts Health NHS Trust
London, United Kingdom
Chase Farm Hospital
London, United Kingdom
Fitzrovia Hospital/QASMC
London, United Kingdom
King's College Hospital
London, United Kingdom
Luton & Dunstable University Hospital
London, United Kingdom
Royal National Orthopaedic Hospital NHS Trust
London, United Kingdom
West Middlesex University Hospital
London, United Kingdom
How to Get in Touch
Jake Taylor-King, DPhil
Sponsor contactCONTACT
Susan O'Connor
Sponsor contactCONTACT